The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Lilly; Merck Serono; MSD; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Chugai Pharma (Inst); Haihe Biopharma (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo (Inst); G1 Therapeutics; GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen (Inst); Lilly; Merck Serono; Merck Serono (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Takeda; Takeda (Inst); Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Hiroshi Sakai
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Merck KGaA; Merck Sharp & Dohme; Ono Pharmaceutical; Taiho Pharmaceutical
 
Masahiro Morise
Speakers' Bureau - AstraZeneca; Chugai/Roche; Lilly; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Kissei Pharmaceutical (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Yuh-Min Chen
No Relationships to Disclose
 
Ji-Youn Han
Honoraria - AstraZeneca; Bristol-Myers Squibb; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Takeda
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda
 
Jin-Ji Yang
No Relationships to Disclose
 
Jun Zhao
No Relationships to Disclose
 
Jason Huang
Employment - Merck KGaA
 
Karin Berghoff
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Rolf Bruns
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Helene Vioix
Employment - Merck KGaA
 
Gordon Otto
Employment - Merck KGaA
Stock and Other Ownership Interests - Novartis
 
Xiuning Le
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Lilly; EMD Serono; Lilly; Spectrum Pharmaceuticals
Research Funding - Boehringer Ingelheim (Inst); Lilly (Inst)
 
Paul K. Paik
Honoraria - Bicara Therapeutics; EMD Serono; Mirati Therapeutics; Takeda; Xencor
Consulting or Advisory Role - Bicara Therapeutics; Calithera Biosciences; EMD Serono; Mirati Therapeutics; Takeda; Xencor
Research Funding - Bicara Therapeutics; Boehringer Ingelheim; EMD Serono